Patents by Inventor Edward HELLRIEGEL

Edward HELLRIEGEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
    Patent number: 11844801
    Abstract: The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: December 19, 2023
    Assignee: Aclaris Therapeutics, Inc.
    Inventors: Walter Smith, Joseph Monahan, Edward Hellriegel, David Gordon, Heidi Hope, John Robert Springer, Gary A. Decrescenzo
  • ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS
    Publication number: 20210338669
    Abstract: The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
    Type: Application
    Filed: March 26, 2021
    Publication date: November 4, 2021
    Inventors: Walter SMITH, Joseph MONAHAN, Edward HELLRIEGEL, David GORDON, Heidi HOPE, John Robert SPRINGER, Gary A. DECRESCENZO